Dextromethorphan shows efficacy in experimental pain (nociception) and opioid tolerance
Related Experiment Video
Updated: Nov 6, 2026

Assessment of Morphine-induced Hyperalgesia and Analgesic Tolerance in Mice Using Thermal and Mechanical Nociceptive Modalities
Published on: July 29, 2014
K J Elliott1, M Brodsky, A Hyanansky
1Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
The oral antitussive dextromethorphan is a clinically available N-methyl-D-aspartate receptor antagonist. Dextromethorphan has analgesic efficacy in the experimental formalin test, blocks the nociceptive activation of the immediate-early gene, c-fos proto-oncogene, and prevents and reverses the development of opiate analgesic tolerance in experimental models. These data suggest that dextromethorphan should be evaluated in a controlled clinical trial for analgesic efficacy in zoster-associated neuralgia.
Insights
Dextromethorphan, an N-methyl-D-aspartate receptor antagonist, shows promise for pain relief. It has demonstrated analgesic effects and can prevent tolerance to other pain medications, suggesting its potential for treating zoster-associated neuralgia.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Research
Background:
- Dextromethorphan is an oral antitussive and a clinically available N-methyl-D-aspartate (NMDA) receptor antagonist.
- NMDA receptors play a role in pain signaling and the development of analgesic tolerance.
Purpose of the Study:
- To evaluate the potential analgesic efficacy of dextromethorphan in zoster-associated neuralgia.
- To explore dextromethorphan's effects on pain pathways and opiate tolerance.
Main Methods:
- Review of existing experimental data on dextromethorphan's pharmacological actions.
- Analysis of dextromethorphan's effects in the formalin test for pain.
- Examination of dextromethorphan's impact on c-fos proto-oncogene expression.
- Assessment of dextromethorphan's role in opiate analgesic tolerance models.
Main Results:
- Dextromethorphan exhibits analgesic efficacy in experimental pain models.
- It blocks nociceptive activation of the c-fos proto-oncogene.
- Dextromethorphan prevents and reverses opiate analgesic tolerance in experimental settings.
Conclusions:
- Experimental data suggest dextromethorphan possesses analgesic properties relevant to neuropathic pain.
- Further investigation in controlled clinical trials is warranted to confirm its efficacy for zoster-associated neuralgia.
Related Concept Videos
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Analgesia and Pain Management
Opioid Receptors: Overview
Opioid Analgesics: Morphine and Other Natural Cogeners
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...

